Maball 500mg Injection

• Non-Hodgkin’s Lymphoma (NHL)
• Chronic Lymphocytic Leukemia (CLL)
• Rheumatoid Arthritis (RA)
• Vasculitis (GPA & MPA)
• Pemphigus Vulgaris

Maball 500mg Injection may cause certain side effects. If side effects occur after administration or last longer than usual, contact your healthcare professional. Regular blood tests are needed to monitor your blood cells and check for hepatitis B. Common side effects are:

• Headache
• Cough
• Fever
• Chills
• Hair loss
• Decrease in WBC
• Skin rash
• Insomnia
• Sore throat

This medicine will be administered by your doctor or nurse. Do not take it on your own.

• Maball 500mg Injection links to the CD20 antigen on both normal and malignant B‑cells.
  
• This binding triggers the immune system to attack and kill the tagged B‑cells.
  
• Stem cells, which lack CD20, survive and later regenerate healthy B‑cells after treatment.
  

​In case you miss a dose, make sure to consult your healthcare provider to get proper guidance. Do not double the dose for compensation.​

At our pharmacy, your health is our top priority. All of our medicines are safe, effective, and approved by leading health authorities. We partner exclusively with reliable and reputable manufacturers, ensuring the highest quality standards in every product we deliver.

Enjoy the convenience of fast home delivery, secure packaging, and affordable prices—plus special discounts on bulk orders. We’re proud to offer international shipping to a wide range of countries across Asia, Europe, Africa, the Americas, and beyond, making trusted healthcare accessible no matter where you are.

Whether you're a patient or a healthcare provider, you can order with confidence and compassion. Our goal is to ensure that quality healthcare reaches everyone, everywhere.


We currently ship to:

Barbados, Haiti, Trinidad and Tobago, Mexico, Bahamas, Ecuador, Peru, Chile, Brazil, Colombia, Philippines, U.K., USA, Kuwait, Saudi Arabia, UAE, Oman, Qatar, Japan, Ireland, Russia, China, France, Australia, Lithuania, Nigeria, Romania, Algeria, Canada, Singapore, Thailand, Hong Kong, Bahrain, Jordan, Indonesia, Hungary, Moldova, Bulgaria, Azerbaijan, Congo, Ethiopia, Lebanon, Morocco, Mozambique, South Korea, Sri Lanka, Belarus, Mongolia, Malaysia, Vietnam, Tunisia, Zambia, and Israel.
Experience the quality everyone’s talking about – order today!

• Feder, O., Amsterdam, D., Ershed, M., et al. (2025). Long‑term efficacy of rituximab in steroid‑dependent and frequent relapsing adult nephrotic syndrome. BMC Nephrology, 26, 126 - https://pubmed.ncbi.nlm.nih.gov/40050772/
  
• Kalenik, V. A., Belada, D., Oliveira, A. C., et al. (2024). Efficacy and safety of rituximab biosimilar (DRL_RI) versus MabThera® in low-tumor-burden follicular lymphoma: The FLINTER study. Blood, 144 (Supplement 1), 6276 - https://pubmed.ncbi.nlm.nih.gov/40421128/https://pubmed.ncbi.nlm.nih.gov/40421128/
  
• Kimby, E. K., Schär, S., Pirosa, M. C., et al. (2025). Six‑month rituximab‑lenalidomide regimen in advanced untreated follicular lymphoma: SAKK 35/10 trial 10‑year update. Blood Advances - https://pmc.ncbi.nlm.nih.gov/articles/PMC11999207/
  
• Maharaj, N., Uppada, D. R., Reddy, N., et al. (2024). Comparing immunogenicity and safety following transition from reference rituximab to biosimilar rituximab (DRL_RI) in patients with rheumatoid arthritis: A randomized, double‑blind, phase 3 study. Arthritis Research & Therapy, 26, 225.
  
• Zheng, X., Di, J., Chen, X., Li, F., Liu, Y., Cao, J., Ning, X., Wei, L., & Zheng, G. (2025). Meta-analysis of the efficacy and safety of rituximab in the treatment of primary Sjögren’s syndrome. Frontiers in Immunology, 16, 1561214.